Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 35

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 35
---
 
      (2,515) 
      764 
      5,150 
      (4,386) 

      Salaries and benefits
       
    309 
      200 
      109 
      632 
      408 
      224 

      Research and development expense before stock-based compensation and depreciation
       
    510 
      2,916 
      (2,406) 
      1,396 
      5,558 
      (4,162) 

      Stock-based compensation
       
    58 
      60 
      (2) 
      127 
      126 
      1 

      Total
       
    568 
      2,976 
      (2,408) 
      1,523 
      5,684 
      (4,161) 

   1 Total third-party research and development expenses are calculated before salaries and benefits and stock-based compensation.

Total
research and development expenses for the three months ended September 30, 2025
were $568, compared to $2,976 for the three months ended September 30, 2024.
The decrease of $2,408 was primarily due to a $2,515 decrease in research
activities mainly due to completion of our GTx-104 pivotal Phase 3 STRIVE-ON
safety clinical trial, partially offset by a $109 increase in salaries and
benefits due to merit increases. 

Total
research and development expenses for the six months ended September 30, 2025
were $1,523, compared to $5,684 for the six months ended September 30, 2024.
The decrease of $4,161 was primarily due to a $4,386 decrease in research
activities mainly due to completion of our GTx-104 pivotal Phase 3 STRIVE-ON
safety clinical trial, partially offset by a $224 increase in salaries and
benefits due to merit increases. 

  33
  

   Stock-based compensation of $58 and $127 for the three and six months ended September 30, 2025, decreased by $2 and increased by $1 compared to $60 and $126 for the three and six months ended September 30